Literature DB >> 29220883

Association of adrenal hormone metabolites and mortality over a 6-year follow-up in COPD patients with acute exacerbation.

Seline Zurfluh1, Manuela Nickler1, Manuel Ottiger1, Christian Steuer2, Alexander Kutz1, Mirjam Christ-Crain3, Werner Zimmerli4, Robert Thomann5, Claus Hoess6, Christoph Henzen7, Luca Bernasconi2, Andreas Huber2, Beat Mueller1, Philipp Schuetz1.   

Abstract

BACKGROUND: The release of hormones from the adrenal gland is vital in acute and chronic illnesses such as chronic obstructive pulmonary disease (COPD) involving recurrent exacerbations. Using a metabolomic approach, we aim to investigate associations of different adrenal hormone metabolites with short- and long-term mortality in COPD patients.
METHODS: We prospectively followed 172 COPD patients (median age 75 years, 62% male) from a previous Swiss multicenter trial. At baseline, we measured levels of a comprehensive spectrum of adrenal hormone metabolites, including glucocorticoid, mineralocorticoid and androgen hormones by liquid chromatography coupled with tandem mass spectrometry (MS). We calculated Cox regression models adjusted for gender, age, comorbidities and previous corticosteroid therapy.
RESULTS: Mortality was 6.4% after 30 days and increased to 61.6% after 6 years. Higher initial androgen hormones predicted lower long-term mortality with significant results for dehydroepiandrosterone (DHEA) [adjusted hazard ratio (HR), 0.82; 95% confidence interval (CI), 0.70-0.98; p=0.026] and dehydroepiandrosterone sulfate (DHEA-S) (adjusted HR, 0.68; 95% CI, 0.50-0.91; p=0.009). An activation of stress hormones (particularly cortisol and cortisone) showed a time-dependent effect with higher levels pointing towards higher mortality at short term, but lower mortality at long term. Activation of the mineralocorticoid axis tended to be associated with increased short-term mortality (adjusted HR of aldosterone, 2.76; 95% CI, 0.79-9.65; p=0.111).
CONCLUSIONS: Independent of age, gender, corticosteroid exposure and exacerbation type, adrenal hormones are associated with mortality at short and long term in patients with COPD exacerbation with different time-dependent effects of glucocorticoids, androgens and mineralocorticoids. A better physiopathological understanding of the causality of these effects may have therapeutic implications.

Entities:  

Keywords:  adrenal hormones; chronic obstructive pulmonary disease; dehydroepiandrosterone; dehydroepiandrosterone sulfate; mortality prediction

Mesh:

Substances:

Year:  2018        PMID: 29220883     DOI: 10.1515/cclm-2017-0873

Source DB:  PubMed          Journal:  Clin Chem Lab Med        ISSN: 1434-6621            Impact factor:   3.694


  7 in total

1.  Low serum DHEA-S is associated with impaired lung function in women.

Authors:  Giancarlo Pesce; Kai Triebner; Diana A van der Plaat; Dominique Courbon; Steinar Hustad; Torben Sigsgaard; Dennis Nowak; Joachim Heinrich; Josep M Anto; Sandra Dorado-Arenas; Jesús Martinez-Moratalla; Jose A Gullon-Blanco; José L Sanchez-Ramos; Chantal Raherison; Isabelle Pin; Pascal Demoly; Thorarinn Gislason; Kjell Torén; Bertil Forsberg; Eva Lindberg; Elisabeth Zemp; Rain Jogi; Nicole Probst-Hensch; Shyamali C Dharmage; Debbie Jarvis; Judith Garcia-Aymerich; Alessandro Marcon; Francisco Gómez-Real; Bénédicte Leynaert
Journal:  EClinicalMedicine       Date:  2020-06-06

Review 2.  An Updated Overview of Metabolomic Profile Changes in Chronic Obstructive Pulmonary Disease.

Authors:  Nan Ran; Zhiqiang Pang; Yinuo Gu; He Pan; Xu Zuo; Xuewa Guan; Yuze Yuan; Ziyan Wang; Yingqiao Guo; Zixu Cui; Fang Wang
Journal:  Metabolites       Date:  2019-06-10

3.  Plasma metabolomics and clinical predictors of survival differences in COPD patients.

Authors:  Victor Pinto-Plata; Ciro Casanova; Miguel Divo; Yohannes Tesfaigzi; Vince Calhoun; Jing Sui; Francesca Polverino; Carmen Priolo; Hans Petersen; Juan Pablo de Torres; Jose Maria Marin; Caroline A Owen; Rebeca Baz; Elizabeth Cordova; Bartolome Celli
Journal:  Respir Res       Date:  2019-10-15

4.  Dehydroepiandrosterone Supplementation May Benefit Women with Asthma Who Have Low Androgen Levels: A Pilot Study.

Authors:  Nadzeya Marozkina; Joe Zein; Mark D DeBoer; Laurie Logan; Laura Veri; Kristie Ross; Benjamin Gaston
Journal:  Pulm Ther       Date:  2019-10-21

Review 5.  Unraveling the Interconnection Patterns Across Lung Microbiome, Respiratory Diseases, and COVID-19.

Authors:  Elisavet Stavropoulou; Konstantia Kantartzi; Christina Tsigalou; Theocharis Konstantinidis; Chrissoula Voidarou; Theodoros Konstantinidis; Eugenia Bezirtzoglou
Journal:  Front Cell Infect Microbiol       Date:  2021-01-28       Impact factor: 6.073

6.  Eosinopenia and neutrophil-to-lymphocyte count ratio as prognostic factors in exacerbation of COPD.

Authors:  Tomasz Karauda; Kamil Kornicki; Amer Jarri; Adam Antczak; Joanna Miłkowska-Dymanowska; Wojciech J Piotrowski; Sebastian Majewski; Paweł Górski; Adam Jerzy Białas
Journal:  Sci Rep       Date:  2021-02-26       Impact factor: 4.379

Review 7.  Androgen and Androgen Receptors as Regulators of Monocyte and Macrophage Biology in the Healthy and Diseased Lung.

Authors:  Mireya Becerra-Diaz; Mason Song; Nicola Heller
Journal:  Front Immunol       Date:  2020-08-07       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.